

Article

Simple and Sensitive Analysis of Clenbuterol in Urine Matrices by UHPLC-MS/MS Method with Online-SPE Sample Preparation

Kristián Slíž^{1,2}, Dominika Olešová³, Juraj Piešťanský^{2,4} and Peter Mikuš^{1,2,*}

¹ Comenius University Bratislava, Faculty of Pharmacy, Department of Pharmaceutical Analysis and Nuclear Pharmacy, Odbojárov 10, 832 32 Bratislava, Slovakia; kristian.sliz@uniba.sk

² Comenius University Bratislava, Faculty of Pharmacy, Toxicologic and Antidoping Centre, Odbojárov 10, 832 32 Bratislava, Slovakia; piestansky@fpharm.uniba.sk

³ Slovak Academy of Sciences, Biomedical Research Center, Institute of Experimental Endocrinology, Dúbravská cesta 9, 845 45 Bratislava, Slovakia; dominika.olesova@savba.sk

⁴ Comenius University Bratislava, Faculty of Pharmacy, Department of Galenic Pharmacy, Odbojárov 10, 832 32 Bratislava, Slovakia

* Correspondence: mikus@fpharm.uniba.sk; Tel.: +421-2-50-117-243

Supplementary Material

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. *Separations* **2022**, *9*, 440. <https://doi.org/10.3390/separations9120440>

Academic Editor: Firstname Lastname

Received: date

Accepted: date

Published: 14 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Table of Contents

Table S1. Gradient of the mobile phase and positions of the switching valve in the SPE–UHPLC–MS/MS method.

Table S2. Recovery and matrix effect of the developed SPE–UHPLC–MS/MS method from the analysis of QC samples in Surine™.

Table S3. Recovery and matrix effect of the developed SPE–UHPLC–MS/MS method from the analysis of QC samples in pooled urine.

Table S4. Stability of clenbuterol from the analysis of QC samples in pooled urine.

Table S5. Comparison of retention time of two MRM transitions for blinded samples in Surine™.

Table S6. Relative abundances of two MRM transitions for blinded samples in Surine™.

Table S7. Comparison of retention time of two MRM transitions for blinded samples in urine.

Table S8. Relative abundances of two MRM transitions for blinded samples in urine.

Table S9. Precision and accuracy of the developed SPE–UHPLC–MS/MS method from analysis of blinded samples in Surine™.

Table S10. Precision and accuracy of the developed SPE–UHPLC–MS/MS method from analysis of blinded samples in urine.

Table S1. Gradient of the mobile phase and positions of the switching valve in the SPE–UHPLC–MS/MS method.

t [min]	Solvent B [%]	Valve Position	Process
0.00	5	1	loading & washing
6.00	5	2	separating & measuring
6.50	5	2	
11.00	95	2	
13.00	95	2	
13.01	5	2	re-equilibrating
17.00	5	1	
20.00	5	1	

Solvent B—methanol

Table S2. Recovery and matrix effect of the developed SPE–UHPLC–MS/MS method from the analysis of QC samples in Surine™.

Nominal [ng/mL]	Found [ng/mL]	Recovery [%], n = 5	Matrix effect without IS [%], n = 5	Matrix effect with IS [%], n = 5
0.5	0.45	101.56	15.84	1.56
2.5	2.35	106.82	15.35	6.82
25	23.64	100.18	-10.53	-0.18

IS—internal standard

Table S3. Recovery and matrix effect of the developed SPE–UHPLC–MS/MS method from the analysis of QC samples in pooled urine.

Nominal [ng/mL]	Found [ng/mL]	Recovery [%], n = 5	Matrix effect without IS [%], n = 5	Matrix effect with IS [%], n = 5
0.5	0.47	106.08	23.04	6.08
2.5	2.47	112.28	20.67	12.28
25	23.77	100.73	-0.44	0.73

IS—internal standard

Table S4. Stability of clenbuterol from the analysis of QC samples in pooled urine.

Conditions	Nominal [ng/mL]	Found [ng/mL]	Recovery [%], n = 5
Autosampler stability in urine at 8°C after 24 h	0.5	0.47	98.09
	2.5	2.41	98.05
	25	25.66	97.67
Freeze–thaw stability in urine (-80°C, after the third cycle)	0.5	0.47	98.68
	2.5	2.36	95.94
	25	25.86	98.40
Benchtop stability in urine after 24 h	0.5	0.47	97.35
	2.5	2.46	100.24
	25	26.44	100.63

Table S5. Comparison of retention time of two MRM transitions for blinded samples in Surine™.

Blinded sample	Retention time IS [min]		Retention time analyte [min]		Difference [%] Max. tolerated: 0.5%
	<i>n</i> = 3		<i>n</i> = 3		
	Sample	Reference	Sample	Reference	
1	9.516	9.526	9.537	9.545	0.09
2	9.480	9.526	9.499	9.545	0.49
3	9.486	9.526	9.506	9.545	0.44
4	9.513	9.526	9.534	9.545	0.13
5	9.488	9.526	9.508	9.545	0.39
6	9.485	9.526	9.496	9.545	0.40
7	9.482	9.526	9.502	9.545	0.45
8	9.518	9.526	9.539	9.545	0.07
9	9.487	9.526	9.497	9.545	0.45
10	9.483	9.526	9.503	9.545	0.44

IS—internal standard

Table S6. Relative abundances of two MRM transitions for blinded samples in Surine™.

Blinded sample	Transition [<i>m/z</i>] = 277	Relative abundance [%]		Difference [%]	Max. toler- ated: Win- dow ±5 (ref- er- ence)
		<i>n</i> = 3			
		Sample	Reference		
1	→ 203	100	100	0.96	>0–
	→ 132.1	5.59	4.63		9.63%
2	→ 203	100	100	0.65	>0–
	→ 132.1	5.28	4.63		9.63%
3	→ 203	100	100	0.32	>0–
	→ 132.1	4.95	4.63		9.63%
4	→ 203	100	100	0.98	>0–
	→ 132.1	5.61	4.63		9.63%
5	→ 203	100	100	0.18	>0–
	→ 132.1	4.81	4.63		9.63%
6	→ 203	100	100	0.54	>0–
	→ 132.1	5.17	4.63		9.63%
7	→ 203	100	100	0.67	>0–
	→ 132.1	5.3	4.63		9.63%
8	→ 203	100	100	1.35	>0–
	→ 132.1	5.98	4.63		9.63%
9	→ 203	100	100	0.68	>0–
	→ 132.1	5.31	4.63		9.63%
10	→ 203	100	100	0.92	>0–
	→ 132.1	5.55	4.63		9.63%

Table S7. Comparison of retention time of two MRM transitions for blinded samples in urine.

Blinded sample	Retention time IS [min]		Retention time analyte [min]		Difference Max. tolerated: 0.5%
	<i>n</i> = 3		<i>n</i> = 3		
	Sample	Reference	Sample	Reference	
1	9.509	9.526	9.527	9.545	0.18
2	9.549	9.526	9.525	9.545	0.23
3	9.542	9.526	9.568	9.545	0.21
4	9.516	9.526	9.536	9.545	0.10
5	9.571	9.526	9.539	9.545	0.26
6	9.545	9.526	9.565	9.545	0.21
7	9.534	9.526	9.554	9.545	0.09
8	9.581	9.526	9.512	9.545	0.46
9	9.519	9.526	9.541	9.545	0.06
10	9.524	9.526	9.527	9.545	0.11

IS—internal standard

Table S8. Relative abundances of two MRM transitions for blinded samples in urine.

Blinded sample	Transition [<i>m/z</i>] = 277	Relative abundance [%] <i>n</i> = 3		Difference [%]	Max. tolerated: Win- dow ±5 (ref- erence)
		Sample	Reference		
1	→ 203	100	100	0.36	>0–
	→ 132.1	4.96	4.63		9.63%
2	→ 203	100	100	1.06	>0–
	→ 132.1	5.69	4.63		9.63%
3	→ 203	100	100	0.6	>0–
	→ 132.1	4.03	4.63		9.63%
4	→ 203	100	100	1.24	>0–
	→ 132.1	5.87	4.63		9.63%
5	→ 203	100	100	0.24	>0–
	→ 132.1	4.87	4.63		9.63%
6	→ 203	100	100	0.28	>0–
	→ 132.1	4.91	4.63		9.63%
7	→ 203	100	100	0.75	>0–
	→ 132.1	5.38	4.63		9.63%
8	→ 203	100	100	0.39	>0–
	→ 132.1	5.02	4.63		9.63%
9	→ 203	100	100	0.1	>0–
	→ 132.1	4.73	4.63		9.63%
10	→ 203	100	100	2.16	>0–
	→ 132.1	6.89	4.63		9.63%

Table S9. Precision (%RSD) and accuracy (%RE) of the developed SPE–UHPLC–MS/MS method from analysis of blinded samples in Surine™.

Blinded Sample	Nominal [ng/mL]	Found [ng/mL]	RSD [%] <i>n</i> = 3	RE [%] <i>n</i> = 3
1	2	1.99	0.56	0
2	40	38.75	1.87	-3
3	1	0.99	3.10	-1
4	2.5	2.71	0.64	-8
5	0.5	0.57	0.36	-12
6	5	5.60	0.92	-11
7	0.2	0.22	1.21	-9
8	1.25	1.21	1.77	-3
9	50	51.64	0.85	-3
10	12.5	13.34	0.46	-6

RSD—relative standard deviation; RE—relative error

Table S10. Precision (%RSD) and accuracy (%RE) of the developed SPE–UHPLC–MS/MS method from analysis of blinded samples in urine.

Blinded Sample	Nominal [ng/mL]	Found [ng/mL]	RSD [%] <i>n</i> = 3	RE [%] <i>n</i> = 3
1	10	10.02	1.34	0
2	2	2.05	0.67	-2
3	0.5	0.48	0.97	-4
4	12.5	12.63	1.33	-1
5	1.25	1.18	0.69	-6
6	1	1.07	5.40	-7
7	50	48.95	0.31	-2
8	0.2	0.21	2.75	-5
9	2.5	2.48	0.17	-1
10	0.4	0.45	1.29	-11

RSD—relative standard deviation; RE—relative error